11:51 AM EST - Fennec Pharmaceuticals Inc : Today announced the U.S. commercial launch and availability of PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. Fennec Pharmaceuticals Inc
shares T.FRX are trading unchanged at $11.00.
